| Isentress (raltegravir) / Merck (MSD) |
| Completed | 1 | 22 | US | Raltegravir, Atazanavir, Reyataz, Atazanavir + Raltegravir | Bristol-Myers Squibb, Merck Sharp & Dohme LLC | HIV Infections | 12/07 | 12/07 | | |
| Completed | 1 | 18 | Europe | Raltegravir then lopinavir/ritonavir, Lopinavir/ritonavir then raltegravir | St Stephens Aids Trust | HIV Infections | 08/08 | 08/08 | | |
NCT01000818: A Study to Evaluate the Effect of Famotidine and Omeprazole on MK0518 (Raltegravir) Pharmacokinetics in Human Immunodeficiency Virus (HIV)-Infected Patients (0518-054) |
|
|
| Completed | 1 | 18 | US | MK0518 (Raltegravir), Raltegravir, famotidine, omeprazole | Merck Sharp & Dohme LLC | HIV-1 Infection, HIV Infections | 03/09 | 03/09 | | |
NCT01047995: Pharmacokinetics (PK) Study of Once Daily Darunavir/Ritonavir and Twice and Once Daily Raltegravir in HIV-infected Subjects |
|
|
| Completed | 1 | 26 | Europe | Raltegravir plus Darunavir/ritonavir, darunavir = TMC114, ritonavir = Norvir trade name, raltegravir = MK-0518, brand name Isentress | St Stephens Aids Trust | HIV Infections | 12/09 | 12/09 | | |
NCT00944307: Effect of Antacids on the Pharmacokinetics of Raltegravir |
|
|
| Completed | 1 | 17 | US | raltegravir, Isentress, antacid, Isentress, Maalox Plus Extra Strength | University of Colorado, Denver | HIV Infections | 12/09 | 12/09 | | |
NCT01027182: Comparison of Concentration-time Course of Plasma and Intracellular Raltegravir in Healthy Volunteers |
|
|
| Completed | 1 | 6 | RoW | Raltegravir, ISENTRESS, 400mg | Changi General Hospital, National University Hospital, Singapore, Merck Sharp & Dohme LLC | Human Immunodeficiency Virus | 03/10 | 03/10 | | |
NCT01101893: A Drug Interaction Study Evaluating GSK2248761 and Raltegravir Pharmacokinetics in Healthy Adult Subjects |
|
|
| Completed | 1 | 15 | US | Raltegravir, GSK2248761, GSK2248761 + Raltegravir | ViiV Healthcare | Infection, Human Immunodeficiency Virus | 06/10 | 06/10 | | |
NCT01241773: TMC435-TiDP16-C123 - A Study in Healthy Volunteers Investigating the Pharmacokinetic Interaction Between TMC435 and the Antiretroviral Agents Efavirenz and Raltegravir |
|
|
| Completed | 1 | 48 | Europe | raltegravir, TMC435 + raltegravir, TMC435, TMC435 + efavirenz, efavirenz | Tibotec Pharmaceuticals, Ireland | Hepatitis C Virus | 04/11 | 04/11 | | |
NCT01253551: VX-950HEP1001 - Drug-drug Interaction Study Between Telaprevir and Raltegravir |
|
|
| Completed | 1 | 21 | US, RoW | Treatment sequence AB, Treatment sequence BA | Tibotec BVBA, Vertex Pharmaceuticals Incorporated | Hepatitis C | | 04/11 | | |
NCT01288755: TMC278-TiDP6-C153 - A Study in Healthy Volunteers Investigating the Pharmacokinetic Interaction Between TMC278 and Raltegravir |
|
|
| Completed | 1 | 24 | Europe | TMC278, Raltegravir | Tibotec Pharmaceuticals, Ireland, Raltegravir is provided by Merck. | HIV Infections | | 05/11 | | |
LIVERAL, NCT01289951: Pharmacokinetic Study of Raltegravir in Human Immunodeficiency Virus/Hepatitis C Virus (HIV/VHC) Coinfected Patients With Advanced (Child-Pugh C) Hepatic Cirrhosis |
|
|
| Completed | 1 | 10 | Europe | Raltegravir 400 mg/12hours | Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal, Merck Sharp & Dohme LLC | Human Immunodeficiency Virus, Hepatitis C | 06/11 | 10/11 | | |
REAL, NCT00667433: Raltegravir as Early Therapy in African-Americans Living With HIV Study |
|
|
| Completed | 1 | 38 | US | Raltegravir + Truvada, MK-0518; Isentress, emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg | David A Wohl, MD, Merck Sharp & Dohme LLC | HIV Infections | 12/11 | 12/11 | | |
NCT01622673: A Pharmacokinetic Study to Evaluate the Effect of Antacids on Raltegravir (MK-0518) in HIV-Infected Participants (MK-0518-247) |
|
|
| Completed | 1 | 27 | US | Raltegravir, RAL, ISENTRESS™, MK-0518, TUMS® Ultra Strength, TUMS, calcium carbonate antacid, MINTOX® Maximum Strength, MINTOX, magnesium/aluminum hydroxide antacid | Merck Sharp & Dohme LLC | HIV Infections | 10/12 | 10/12 | | |
NCT01525628: Drug Drug Interaction Study Between BI 201335 and BI 207127 in Chronic Hepatitis C Infected Patients |
|
|
| Completed | 1 | 72 | US, Canada, Europe | midazolam, BI 201335, tenofovir, caffeine, tolbutamide, pegylated interferon, BI 207127, ribavirin | Boehringer Ingelheim | Hepatitis C, Chronic | 12/13 | 10/14 | | |
NCT01930045: A Pharmacokinetic Study to Evaluate the Effect of MAALOX on Raltegravir (MK-0518) in Human Immunodeficiency Virus (HIV)-Infected Participants (MK-0518-295) |
|
|
| Completed | 1 | 18 | NA | Raltegravir (ISENTRESS™), MAALOX (MAL), MAALOX® MS | Merck Sharp & Dohme LLC | HIV Infections | 12/13 | 12/13 | | |
